Resumo
Objetivo: Abordar a relação entre a Fibromialgia (FM) e saúde do trato gastrointestinal (TGI) e sua importância para o diagnóstico e tratamento da FM. Revisão bibliográfica: A FM é um quadro reumatológico caracterizado, principalmente, por dor crônica difusa. Outras manifestações possíveis envolvem fadiga, alteração do sono, acometimento cognitivo, distúrbios de humor e sintomas gastrointestinais. Existe uma relação muito próxima entre a FM e afecções gastrointestinais e o diagnóstico bem-feito, tal como a boa avaliação do paciente, são necessárias para alcançar o melhor resultado terapêutico possível. Considerações finais: Ainda que pouco elucidada, há uma estreita correlação entre a FM e o TGI. Portanto, é importante valorizar a sintomatologia e conhecer a relação bidirecional entre FM e afecções do TGI, sobretudo a síndrome do intestino irritável (SII). Contudo, necessitamos de mais estudos que explorem a etiopatogenia e a fisiopatologia da FM, tal como a influência do TGI nesses aspectos, para melhorar tanto o diagnóstico quanto o tratamento da FM.
Referências
ALBAYRAK B, et al. Investigating of relation between fibromyalgia syndrome and intestinal microbiota. Mikrobiyol Bul, 2021; 55(2): 146-160.
ALBRECHT PJ e RICE FL. Fibromyalgia syndrome pathology and environmental influences on afflictions with medically unexplained symptoms. Rev Environ Health, 2016; 31(2): 281-294.
ATZENI F, et al. Rheumatic manifestations in inflammatory bowel disease. Autoimmun Rev, 2014; 13(1): 20-23.
BAYRAK M. Metabolic syndrome, depression, and fibromyalgia syndrome prevalence in patients with irritable bowel syndrome: A case-control study. Medicine (Baltimore), 2020; 99(23): e20577.
BERSTAD A, et al. Functional bowel symptoms, fibromyalgia and fatigue: A food-induced triad?. Scand J Gastroenterol, 2012; 47(8-9): 914-919.
CHEN JH, et al. Is Fibromyalgia Risk Higher Among Male and Young Inflammatory Bowel Disease Patients? Evidence from a Taiwan Cohort of One Million. Pain Physician, 2018; 21(3): 257-264.
CLOS-GARCIA M, et al. Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia. EBioMedicine, 2019; 46(1): 499-511.
ERDRICH S, et al. A systematic review of the association between fibromyalgia and functional gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 2020; 13: 1-17.
ERDRICH S, et al. Determining the association between fibromyalgia, the gut microbiome and its biomarkers: A systematic review. BMC Musculoskelet Disord, 2020; 21(181): 1-12.
FREIDIN MB, et al. An association between chronic widespread pain and the gut microbiome. Rheumatology (Oxford), 2021; 60(8): 3727-3737.
GALVEZ-SÁNCHEZ CM, et al. Psychological impact of fibromyalgia: current perspectives. Psychol Res Behav Manag, 2019; 12(1): 117-127.
GARCÍA-LEIVA JM, et al. Celiac symptoms in patients with fibromyalgia: a cross-sectional study. Rheumatology International, 2014; 35(3): 561-567.
GOTA CE. Fibromyalgia Recognition and Management in the Primary Care Office. Med Clin North Am, 2021; 105(2): 285-296.
HAUSTEINER-WIEHLE C e HENNINGSEN P. Irritable bowel syndrome: Relations with functional, mental, and somatoform disorders. World J Gastroenterol, 2014; 20(20): 6024-6030.
HEIDARI F, et al. Prevalence of fibromyalgia in general population and patients, a systematic review and meta‐analysis. Rheumatol Int, 2017; 37(9): 1527-1539.
HEYMANN RE, et al. Consenso brasileiro do tratamento da fibromialgia. Rev Bras Reumatol, 2010; 50(1): 56-66.
HEYMANN RE, et al. Novas diretrizes para o diagnóstico da fibromialgia. Rev Bras Reumatol, 2017; 57(2): 467-476.
HOD K, et al. Bloating in Irritable Bowel Syndrome Is Associated with Symptoms Severity, Psychological Factors, and Comorbidities. Digestive Diseases and Sciences, 2018; 64(5): 1288-1295.
JOHNSON CM e MAKAI GEH. Fibromyalgia and Irritable Bowel Syndrome in Female Pelvic Pain. Semin Reprod Med, 2018; 36(2): 136-142.
KLEYKAMP BA, et al. The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review. Semin Arthritis Rheum, 2021; 51(1): 166-174.
KOECHLIN H, et al. Placebo responses and their clinical implications in fibromyalgia: a meta-analysis using SSRI and SNRI trials. Front Pain Res (Lausanne), 2021; 2:750523.
MACFARLANE GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis, 2017; 76(2): 318-328.
MCCARBERG BH. Clinical overview of fibromyalgia. Am J Ther, 2012; 19(5): 357-368.
MINERBI A, et al. Altered microbiome composition in individuals with fibromyalgia. Pain, 2019; 160(11): 2589-2602.
MINERBI A e FITZCHARLES MA. Gut microbiome: pertinence in fibromyalgia. Clin Exp Rheumatol, 2020; 123(1): 99-104.
NISIHARA R, et al. Celiac disease and fibromyalgia: Is there an association?. Rev Esp Enferm Dig, 2016; 108(2): 107-108.
OLIVE LS, et al. Fatigue, Physical Activity, and Mental Health in People Living With Inflammatory Bowel Disease, Fibromyalgia, and in Healthy Controls: A Comparative Cross-Sectional Survey. Gastroenterol Nurs, 2020; 43(2): 172-185.
OTU-NYARKO CG, et al. Disability in Children and Adolescents With Irritable Bowel Syndrome and/or Fibromyalgia. J Pediatr Gastroenterol Nutr, 2015; 61(5): 558-560.
PEARSON J, et al. A feasibility randomised controlled trial of a fibromyalgia self- management programme in a community setting with a nested qualitative study (FALCON): Study protocol. Musculoskeletal Care, 2021; 19(1): 59-66.
RODRIGO L, et al. Remarkable prevalence of coeliac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study. Arthritis Res Ther, 2013; 15(6): 1-12.
SETTEMBRE C, et al. Association among Disorders of Gut-Brain Interaction (DGBI) and Fibromyalgia: A Prospective Study. J Clin Med, 2022; 11(3): 809.
SIRACUSA R, et al. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci, 2021; 22(8): 3891.
SLIM M, et al. An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms. Rheumatol Int, 2015; 35(3): 433-444.
TECKCHANDANI S, et al. Metabolomics in Chronic Pain Research. Eur J Pain, 2021; 25(2): 313-326.
TOMASELLO G, et al. Intestinal dysbiosis and hormonal neuroendocrine secretion in the fibromyalgic patient. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018; 162(4): 258-262.
TOVOLI F, et al. Fibromyalgia and coeliac disease: a media hype or an emerging clinical problem?. Clin Exp Rheumatol, 2013; 31(6): 50-52.
ÜÇÜNCÜ MZ, et al. The early diagnosis of fibromyalgia in irritable bowel syndrome patients. Medical Hypotheses, 2020; 143:110119.
WOLFE F, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Seminars in Arthritis and Rheumatism, 2016; 46(3): 319-329.
WOLFE F, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research, 2010; 62(5): 600-610.
YANG TY, et al. Risk for Irritable Bowel Syndrome in Fibromyalgia Patients: A National Database Study. Medicine (Baltimore), 2017; 96(14): e6657.
